Pharmaceutical company ”Sotex” was established in 1999.

Initially, the company was engaged in licensed production, as part of partnership with well-known western manufacturers, such as Nycomed, Lek, Pliva, KRKA. This enabled the company to gain production and product quality control experience in accordance with western standards.

2005

•  An injectable dosage form manufacture with capacity of 100 million ampoules per year is launched. The ”Sotex” factory becomes one of the first facilities in Russia fully complying with GMP EU requirements.

2006

• Launch of licensed injectable medicine production in cooperation with Nycomed.
• ”Sotex” starts producing solid dosage forms by placing orders at European pharmaceutical factories

2007

• ”Sotex” enters TOP-10 leading Russian pharmaceutical manufacturers.
• The company starts selling products under its own brands: Cereton® and Angiozil® Retard.
• “Sotex “PharmFirm” becomes a member of the Association of Russian Pharmaceutical Manufacturers (ARPM), which unites leaders of the pharmaceutical market.

2008

• “Sotex” enters into a contract with the Federal State Unitary Enterprise “State Scientific Research Institute of Highly Pure Biopreparations” of the Federal Medical and Biological Agency, under which all exclusive rights to produce, market and sell Epocrin® are assigned to “Sotex “PharmFirm”.
• The company launches a pre-filled syringe line aimed for production of genetically engineered drugs. The first product on the new line was Eralfon® (epoetin alfa) used in such socially significant fields as oncology and nephrology.
• Acquisition of 67% shares of the biotechnology company “Protein Contour”.

2009

• “Sotex” starts exporting medicinal products to CIS and non-CIS countries. 
• “Sotex” continues to expand its range of own brands by launching such products as: Listab 75®, CompligamB®, Flamax®, Dolomin®.
• The Federal Antimonopoly Service of the Russian Federation confirmed the complete interchangeability of Eralfon® and its western equivalent, basing on the material analysis and the medical experts and clinicians opinion.
• Production of syringes with automatic needle shielding system was launched.

2010

• “Sotex” has launched a new brand – Nejrox, and obtained the patent for invention of a drug formulation with improved stability properties.
• Amelotex® in tablets and Flamax® in ampoules are now available.

Picture Gallery of the Enterprise's History